bioRxiv Science⌕ Search

Biology subjects

Marchante, M.

Publications and source records attributed to Marchante, M..

4 recordsLinked to original sources

Reproducible differentiation of pure ovarian support cells from clinical-grade hiPSCs as a novel infertility treatment

In vitro maturation (IVM) is an infertility treatment used during in vitro fertilization (IVF) procedures in which immature oocytes are matured outside the body, limiting the excessive hormone doses required for retrieval of ready-to-fertilize oocytes. To overcome the historically low embryo formation rate associated with IVM, we have recently demonstrated that co-culture of hiPSC-derived ovarian support cells (OSCs) yielded higher rates of oocyte maturation and euploid embryo formation, by mimicking the complex ovarian environment in vitro, offering a novel solution to overcome the IVM main limitation. To translate this process into clinics, we sourced and engineered a compliant female clinical-grade (CG) hiPSC line to derive OSCs with similar quality attributes and clinical outcomes to results previously demonstrated with a research hiPSC line. We further optimized our manufacturing protocols to enable increased scale and substituted reagents with appropriate higher-quality alternatives. This strategic approach to product development has successfully met scalable manufacturing needs and ultimately resulted in a product of improved reproducibility, purity, and efficacy. Our findings support the use of a similar strategy to fine-tune hiPSC-derived products facilitating translation to clinical applications.

bioengineering↗

Ovarian support cell in vitro maturation (OSC-IVM) results in healthy murine live births with no evidence of reprotoxicology in a multigenerational study

Study questionDoes application of human stem cell-derived ovarian support cells (OSCs) for in vitro maturation (IVM) have a safe reproductive toxicity profile? Summary answerThe use of OSC-IVM co-culture improves blastocyst formation in a mouse model and results in healthy live births with no evidence of reprotoxicity. What is known alreadyAbbreviated stimulation to obtain immature oocytes combined with a successful IVM offers a promising alternative to traditional in vitro fertilization, reducing hormonal doses and making IVF shorter and safer. Recently, we developed an OSC platform derived from human induced pluripotent stem cells (hiPSCs) that replicate dynamic ovarian function in vitro, enhancing human oocyte maturation and yielding an improved blastocyst formation rate compared to commercial IVM options. However, the reproductive toxicity profile, commonly assessed via murine multigenerational models, for OSC-IVM remains unknown. Study design, size, durationA total of 70 B6/CBA 6-8-week-old stimulated female mice were used in this study to collect immature mouse oocytes (n=2,025) at the germinal vesicle (GV) stage. Half of these oocytes were retrieved denuded (denuded oocytes condition, n= 930), while the remaining oocytes were kept with the cumulus cells (COCs condition, n= 1,095) to simulate the two possible dispositions of oocytes during clinical practice. Oocytes from each condition, denuded oocytes and COCs, were randomly assigned to either commercially available traditional IVM media (MediCult-IVMTM, Origio) group (control group) or the same traditional IVM media supplemented with human OSCs (FertiloTM, Gameto Inc.) to form the OSC-IVM group (test group). Participants/materials, setting, methodsOocytes from each condition, denuded oocytes and COCs, were subjected to in vitro culture for 18-20 hours. After IVM, metaphase II (M2) oocytes were inseminated by intracytoplasmic sperm injection (ICSI) and cultured to assess blastocyst formation in vitro. Embryos that reached the blastocyst stage on day five were vitrified using Kitazatos protocol in preparation for embryo transfers. A group of M2 oocytes and blastocyst embryos were employed for quality analyses by immunofluorescence. Vitrified blastocysts were warmed and transferred to pseudopregnant females (4-5 embryos per uterine horn), evaluating the F1 offspring. Pup characteristics were tracked, including weight, length, sex ratio, and physiology. Weekly monitoring assessed mouse behavior and development. At reproductive age, select F1 mice were outbred to wildtype mice to produce the F2 generation, analyzing live births, sex ratio, morphology, and behavior across groups. Moreover, hormonal and organ histological analyses were performed in F1 mice to further explore the overall health of the progeny. Main results and the role of chanceIn contrast to findings in humans, in mice OSC-IVM generally led to a decreased maturation rate compared to Traditional-IVM (68.6% {+/-} 14.1% versus 80.9% {+/-} 5.9%, p=0.0101). Subsequent embryo culture yielded significantly different fertilization rates between the four groups (p=0.0055). Specifically, OSC-IVM with COCs significantly differed from Traditional-IVM with denuded oocytes (89.5 {+/-} 10.5 versus 96.5 {+/-} 4.8, p=0.0098). There were no differences in the cleavage rates (p=0.7547). However, there was a significant distinction in the blastocyst formation (p=0.0068), wherein OSC-IVM with COCs showed a greater formation rate compared to Traditional-IVM for both denuded oocytes and COCs (56.1% {+/-} 19.2% versus 41.5% {+/-} 15.9% and 38.0% {+/-} 16.2%; p=0.0408, and p=0.0063). Spindle morphology analysis demonstrated normal spindle morphology in denuded oocytes and COCs under both Traditional-IVM and OSC-IVM. Moreover, embryo analysis showed no significant difference in inner cell mass count (p=0.1550). Following embryo transfers, analysis of live births showed no significant distinctions between groups regarding delivery, sex ratio, pup length, developmental and behavioral abnormalities, hormonal values or histopathological anomalies in the F1 generation. Evaluation of the F2 generation also showed no significant differences in live births, sex ratio, or developmental/behavioral abnormalities between groups, further validating the absence of long-term implications and transgenerational effects derived from OSC-IVM culture. Limitations, reasons for cautionAlthough this study was conducted in compliance with European Medicines Agency (EMA) ICH E6 (R2) Good clinical practice scientific guidelines to demonstrate the OSC safety, human clinical studies evaluating in vivo and live birth outcomes are necessary to corroborate the findings of this study. Wider implications of the findingsThis study provides evidence of the safety of using the OSC-IVM system, as evidenced by the lack of adverse effects on in vitro embryo development post OSC-IVM and on the health and fertility of offspring across successive generations in vivo. Trial registration numberN/A

pharmacology and toxicology↗

Improved rescue of immature oocytes obtained from conventional gonadotropin stimulation cycles via human induced pluripotent stem cell-derived ovarian support cell co-culture

Structured AbstractO_ST_ABSPurposeC_ST_ABSTo determine if rescue in vitro maturation (IVM) of human oocytes can be improved by co-culture with ovarian support cells (OSCs) derived from human induced pluripotent stem cells (hiPSCs). MethodsFertility patients undergoing conventional ovarian stimulation for oocyte cryopreservation or IVF donated denuded immature germinal vesicle (GV) and metaphase I (MI) oocytes for research, which were allocated between either the control or intervention cultures. Fertility patients aged 25 to 45 years old donated immature oocytes under informed consent, with no additional inclusion criteria. The 24-28 hour OSC-IVM culture condition was composed of 100,000 OSCs in suspension culture with human chorionic gonadotropin (hCG), recombinant follicle stimulating hormone (rFSH), androstenedione and doxycycline supplementation. The Media-IVM control lacked OSCs and contained the same supplementation. Primary endpoints consisted of MII formation rate and morphological quality assessment. Additionally, metaphase spindle assembly location and oocyte transcriptomic profiles were assessed compared to in vivo matured MII oocyte controls. ResultsWe observed significant improvement in maturation outcome rates ([~]1.7X) for oocytes that underwent IVM with OSCs. Specifically, the OSC-IVM group yielded a maturation rate of 62% {+/-} 5.57% SEM versus 37% {+/-} 8.96% SEM in the Media-IVM (p=0.0138, unpaired t-test). Oocyte morphological quality between OSC-IVM and the Media-IVM control did not significantly differ. OSC-IVM resulted in MII oocytes with no instances of spindle absence and no significant difference in position compared to in vivo matured IVF-MII controls. OSC-IVM treated MII oocytes display a transcriptomic signature significantly more similar to IVF-MII controls than the Media-IVM control MII oocytes did. ConclusionThe novel OSC-IVM platform is an effective tool for rescue maturation of human oocytes obtained from conventional stimulation cycles, yielding oocytes with improved nuclear and cytoplasmic maturation. OSC-IVM shows broad utility for application in modern fertility treatment to improve the total number of available mature oocytes for fertility treatment.

developmental biology↗

Human induced pluripotent stem cell-derived ovarian support cell co-culture improves oocyte maturation in vitro after abbreviated gonadotropin stimulation

Assisted reproductive technologies (ART) have significantly impacted fertility treatment worldwide through innovations such as in vitro fertilization (IVF) and in vitro maturation (IVM). IVM holds promise as a technology for fertility treatment in women who cannot or do not wish to undergo conventional controlled ovarian stimulation (COS). However, IVM has historically shown highly variable performance in maturing oocytes and generating oocytes with strong developmental capacity. Furthermore, recently reported novel IVM approaches are limited to use in cycles lacking human chorionic gonadotropin (hCG) triggers, which is not standard practice in fertility treatment. We recently reported the development of ovarian support cells (OSCs) generated from human induced pluripotent stem cells (hiPSCs) that recapitulate dynamic ovarian function in vitro. Here we investigate the potential of the se OSCs in an IVM co-culture system to improve the maturation of human cumulus-enclosed immature oocytes retrieved from abbreviated gonadotropin stimulated cycles. We reveal that OSC-IVM significantly improves maturation rates compared to existing IVM systems. Most importantly, we demonstrate that OSC-assisted IVM oocytes are capable of significantly improving euploid blastocyst formation and yielding blastocysts with normal global and germline differential methylation region methylation profiles, a key marker of their clinical utility. Together, these findings demonstrate a novel approach to IVM with broad applicability to modern ART practice. Structured AbstractO_ST_ABSObjectiveC_ST_ABSTo determine if in vitro maturation (IVM) of human oocytes can be improved by co-culture with ovarian support cells (OSCs) derived from human induced pluripotent stem cells (hiPSCs). DesignThree independent experiments were performed in which oocyte donors were recruited to undergo abbreviated gonadotropin stimulation and retrieved cumulus oocyte complexes (COCs) were randomly allocated between the OSC-IVM and control IVM conditions. SubjectsAcross the three experiments, a total of 67 oocyte donors aged 19 to 37 years were recruited for retrieval using informed consent. Anti-mullerian hormone (AMH) value, antral follicle count (AFC), age, BMI, and ovarian pathology were used for inclusion and exclusion criteria. Intervention and ControlThe OSC-IVM culture condition was composed of 100,000 OSCs in suspension culture supplemented with human chorionic gonadotropin (hCG), recombinant follicle stimulating hormone (rFSH), androstenedione and doxycycline. IVM controls comprised commercially-available IVM media without OSCs and contained either the same supplementation as above (media-matched control), or FSH and hCG only (IVM media control). In one experiment, an additional control using fetal ovarian somatic cells (FOSCs) was used with the same cell number and media conditions as in the OSC-IVM. Main Outcome MeasuresPrimary endpoints consisted of metaphase II (MII) formation rate and oocyte morphological quality assessment. A limited cohort of oocytes were utilized for secondary endpoints, consisting of fertilization and blastocyst formation rates with preimplantation genetic testing for aneuploidy (PGT-A) and embryo epigenetic analysis. ResultsOSC-IVM resulted in a statistically significant improvement in MII formation rate compared to the media-matched control, a commercially available IVM media control, and the FOSC-IVM control. Oocyte morphological quality between OSC-IVM and controls did not significantly differ. OSC-IVM displayed a trend towards improved fertilization, cleavage, and blastocyst formation. OSC-IVM showed statistically significant improvement in euploid day 5 or 6 blastocyst formation compared to the commercially available IVM media control. OSC-IVM embryos displayed similar epigenetic global and germline loci profiles compared to conventional stimulation and IVM embryos. ConclusionThe novel OSC-IVM platform is an effective tool for maturation of human oocytes obtained from abbreviated gonadotropin stimulation cycles, supporting/inducing robust euploid blastocyst formation. OSC-IVM shows broad utility with different stimulation regimens, including hCG triggered and untriggered oocyte retrieval cycles, making it a highly useful tool for modern fertility treatment.

developmental biology↗